Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valbenazine for Demoralization in Tardive Dyskinesia
NCT05053321Phase 1Withdrawn
- Sponsor
- Yale University
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of valbenazine in tardive dyskinesia (TD), sponsored by Yale University. Primary endpoint: Change in Demoralization Scale at 6 weeks. Planned start Oct 2024; status: withdrawn.
02
Drugs
valbenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on NCT05053321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053321.